- StageZero Life Sciences Ltd. (SZLS) announced new strategies for employers to help improve outcomes for employees with cancer at any given stage of their diagnosis
- StageZero is working with self-funded employers to treat cancer early via its program
- Several program features help address the early signs for multiple types of cancers
- StageZero is a healthcare company improving the early detection and management of cancer and other chronic diseases
- StageZero Life Sciences Ltd. (SZLS) is unchanged trading at $0.09 per share as of 12:49 p.m. ET
StageZero Life Sciences (SZLS) announced new strategies for employers to help improve outcomes for employees with cancer at any given stage of their diagnosis.
The company shared that its program includes state-of-the-art, early-stage cancer testing, interventional support for those who need it, and innovative telehealth care. StageZero stated it is working with self-funded employers regarding the program to treat cancer early.
“At StageZero, we are dedicated to improving cancer outcomes at every stage and we are proud to team up with employers to make that a reality… Our new employer program builds on those efforts by finding, intervening, and treating cancer early to help improve patient outcomes,” James Howard-Tripp, Chairman and CEO of StageZero, said.
One feature of the program, Aristotle, is an mRNA multi-cancer panel for simultaneously screening multiple cancers from a single blood sample with high sensitivity and specificity for each tumour.
The AVRT feature allegedly helps identify and address the early warning signs of cancer through an advanced panel of tests not typically offered in routine exams.
The company stated its cancer therapies provided through its clinics target metabolic pathways in patients with cancer. It is personalized for each patient and is focused on key markers of metabolic and inflammatory health, which may improve cancer recovery outcomes.
StageZero is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and telehealth programs.
StageZero Life Sciences Ltd. (SZLS) is unchanged trading at $0.09 per share as of 12:49 p.m. ET.